- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease ; volume:8 ; number:1 ; day:27 ; month:4 ; year:2016 ; pages:1-11 ; date:12.2016
Alzheimer's research & therapy ; 8, Heft 1 (27.4.2016), 1-11, 12.2016
- Urheber
-
Henjum, Kristi
- Beteiligte Personen und Organisationen
-
Almdahl, Ina S.
Årskog, Vibeke
Minthon, Lennart
Hansson, Oskar
Fladby, Tormod
Nilsson, Lars N. G.
SpringerLink (Online service)
- DOI
-
10.1186/s13195-016-0182-1
- URN
-
urn:nbn:de:1111-2016042933359
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Henjum, Kristi
- Almdahl, Ina S.
- Årskog, Vibeke
- Minthon, Lennart
- Hansson, Oskar
- Fladby, Tormod
- Nilsson, Lars N. G.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume